Golimumab  ||| S:0 E:10 ||| NNP
for  ||| S:10 E:14 ||| IN
the  ||| S:14 E:18 ||| DT
treatment  ||| S:18 E:28 ||| NN
of  ||| S:28 E:31 ||| IN
psoriatic  ||| S:31 E:41 ||| JJ
arthritis  ||| S:41 E:51 ||| NN
This  ||| S:51 E:56 ||| DT
paper  ||| S:56 E:62 ||| NN
presents  ||| S:62 E:71 ||| VBZ
a  ||| S:71 E:73 ||| DT
summary  ||| S:73 E:81 ||| NN
of  ||| S:81 E:84 ||| IN
the  ||| S:84 E:88 ||| DT
evidence  ||| S:88 E:97 ||| NN
review  ||| S:97 E:104 ||| NN
group  ||| S:104 E:110 ||| NN
( ||| S:110 E:111 ||| -LRB-
ERG ||| S:111 E:114 ||| NNP
)  ||| S:114 E:116 ||| -RRB-
report  ||| S:116 E:123 ||| NN
into  ||| S:123 E:128 ||| IN
the  ||| S:128 E:132 ||| DT
use  ||| S:132 E:136 ||| NN
of  ||| S:136 E:139 ||| IN
golimumab  ||| S:139 E:149 ||| NN
for  ||| S:149 E:153 ||| IN
the  ||| S:153 E:157 ||| DT
treatment  ||| S:157 E:167 ||| NN
of  ||| S:167 E:170 ||| IN
psoriatic  ||| S:170 E:180 ||| JJ
arthritis  ||| S:180 E:190 ||| NN
( ||| S:190 E:191 ||| -LRB-
PsA ||| S:191 E:194 ||| NNP
) ||| S:194 E:195 ||| -RRB-
.  ||| S:195 E:197 ||| .
The  ||| S:197 E:201 ||| DT
main  ||| S:201 E:206 ||| JJ
clinical  ||| S:206 E:215 ||| JJ
effectiveness  ||| S:215 E:229 ||| NN
data  ||| S:229 E:234 ||| NNS
were  ||| S:234 E:239 ||| VBD
derived  ||| S:239 E:247 ||| VBN
from  ||| S:247 E:252 ||| IN
a  ||| S:252 E:254 ||| DT
single  ||| S:254 E:261 ||| JJ
phase  ||| S:261 E:267 ||| NN
III  ||| S:267 E:271 ||| NNP
randomised  ||| S:271 E:282 ||| VBD
controlled  ||| S:282 E:293 ||| VBN
trial  ||| S:293 E:299 ||| NN
( ||| S:299 E:300 ||| -LRB-
RCT ||| S:300 E:303 ||| NNP
:  ||| S:303 E:305 ||| :
GO-REVEAL ||| S:305 E:314 ||| NNP
)  ||| S:314 E:316 ||| -RRB-
that  ||| S:316 E:321 ||| IN
compared  ||| S:321 E:330 ||| VBN
golimumab  ||| S:330 E:340 ||| VBN
with  ||| S:340 E:345 ||| IN
placebo  ||| S:345 E:353 ||| NN
for  ||| S:353 E:357 ||| IN
treating  ||| S:357 E:366 ||| VBG
patients  ||| S:366 E:375 ||| NNS
with  ||| S:375 E:380 ||| IN
active  ||| S:380 E:387 ||| JJ
and  ||| S:387 E:391 ||| CC
progressive  ||| S:391 E:403 ||| JJ
PsA  ||| S:403 E:407 ||| NN
who  ||| S:407 E:411 ||| WP
were  ||| S:411 E:416 ||| VBD
symptomatic  ||| S:416 E:428 ||| VBN
despite  ||| S:428 E:436 ||| IN
the  ||| S:436 E:440 ||| DT
use  ||| S:440 E:444 ||| NN
of  ||| S:444 E:447 ||| IN
previous  ||| S:447 E:456 ||| JJ
disease-modifying  ||| S:456 E:474 ||| JJ
antirheumatic  ||| S:474 E:488 ||| JJ
drugs  ||| S:488 E:494 ||| NNS
or  ||| S:494 E:497 ||| CC
non-steroidal  ||| S:497 E:511 ||| JJ
anti-inflammatory  ||| S:511 E:529 ||| JJ
drugs ||| S:529 E:534 ||| NNS
.  ||| S:534 E:536 ||| .
The  ||| S:536 E:540 ||| DT
14-week  ||| S:540 E:548 ||| CD
data  ||| S:548 E:553 ||| NNS
showed  ||| S:553 E:560 ||| VBD
that ||| S:560 E:564 ||| IN
,  ||| S:564 E:566 ||| ,
compared  ||| S:566 E:575 ||| VBN
with  ||| S:575 E:580 ||| IN
placebo ||| S:580 E:587 ||| NN
,  ||| S:587 E:589 ||| ,
golimumab  ||| S:589 E:599 ||| CD
50  ||| S:599 E:602 ||| CD
mg  ||| S:602 E:605 ||| NNS
significantly  ||| S:605 E:619 ||| RB
improved  ||| S:619 E:628 ||| VBN
joint  ||| S:628 E:634 ||| JJ
disease  ||| S:634 E:642 ||| NN
response  ||| S:642 E:651 ||| NN
as  ||| S:651 E:654 ||| IN
measured  ||| S:654 E:663 ||| VBN
by  ||| S:663 E:666 ||| IN
American  ||| S:666 E:675 ||| NNP
College  ||| S:675 E:683 ||| NNP
of  ||| S:683 E:686 ||| IN
Rheumatology  ||| S:686 E:699 ||| NNP
( ||| S:699 E:700 ||| -LRB-
ACR ||| S:700 E:703 ||| NNP
)  ||| S:703 E:705 ||| -RRB-
20  ||| S:705 E:708 ||| CD
[ ||| S:708 E:709 ||| -LRB-
relative  ||| S:709 E:718 ||| JJ
risk  ||| S:718 E:723 ||| NN
( ||| S:723 E:724 ||| -LRB-
RR ||| S:724 E:726 ||| NNP
)  ||| S:726 E:728 ||| -RRB-
5.73 ||| S:728 E:732 ||| NNP
,  ||| S:732 E:734 ||| ,
95 ||| S:734 E:736 ||| CD
%  ||| S:736 E:738 ||| NN
confidence  ||| S:738 E:749 ||| NN
interval  ||| S:749 E:758 ||| NNS
( ||| S:758 E:759 ||| -LRB-
CI ||| S:759 E:761 ||| NNP
)  ||| S:761 E:763 ||| -RRB-
3.24  ||| S:763 E:768 ||| CD
to  ||| S:768 E:771 ||| TO
10.56 ||| S:771 E:776 ||| CD
]  ||| S:776 E:778 ||| -RRB-
and  ||| S:778 E:782 ||| CC
Psoriatic  ||| S:782 E:792 ||| NNP
Arthritis  ||| S:792 E:802 ||| NNP
Response  ||| S:802 E:811 ||| NNP
Criteria  ||| S:811 E:820 ||| NNP
( ||| S:820 E:821 ||| -LRB-
PsARC ||| S:821 E:826 ||| NNP
)  ||| S:826 E:828 ||| -RRB-
( ||| S:828 E:829 ||| -LRB-
RR  ||| S:829 E:832 ||| NNP
3.45 ||| S:832 E:836 ||| CD
,  ||| S:836 E:838 ||| ,
95 ||| S:838 E:840 ||| CD
%  ||| S:840 E:842 ||| NN
CI  ||| S:842 E:845 ||| NNP
2.49  ||| S:845 E:850 ||| CD
to  ||| S:850 E:853 ||| TO
4.87 ||| S:853 E:857 ||| CD
) ||| S:857 E:858 ||| -RRB-
,  ||| S:858 E:860 ||| ,
and  ||| S:860 E:864 ||| CC
skin  ||| S:864 E:869 ||| NN
disease  ||| S:869 E:877 ||| NN
response  ||| S:877 E:886 ||| NN
as  ||| S:886 E:889 ||| IN
measured  ||| S:889 E:898 ||| VBN
by  ||| S:898 E:901 ||| IN
the  ||| S:901 E:905 ||| DT
Psoriasis  ||| S:905 E:915 ||| NNP
Area  ||| S:915 E:920 ||| NNP
and  ||| S:920 E:924 ||| CC
Severity  ||| S:924 E:933 ||| NNP
Index  ||| S:933 E:939 ||| NNP
( ||| S:939 E:940 ||| -LRB-
PASI ||| S:940 E:944 ||| NNP
)  ||| S:944 E:946 ||| -RRB-
75  ||| S:946 E:949 ||| CD
( ||| S:949 E:950 ||| -LRB-
RR  ||| S:950 E:953 ||| NNP
15.95 ||| S:953 E:958 ||| NNP
,  ||| S:958 E:960 ||| ,
95 ||| S:960 E:962 ||| CD
%  ||| S:962 E:964 ||| NN
CI  ||| S:964 E:967 ||| NNP
4.62  ||| S:967 E:972 ||| NNP
to  ||| S:972 E:975 ||| TO
59.11 ||| S:975 E:980 ||| CD
) ||| S:980 E:981 ||| -RRB-
.  ||| S:981 E:983 ||| .
The  ||| S:983 E:987 ||| DT
24-week  ||| S:987 E:995 ||| JJ
absolute  ||| S:995 E:1004 ||| JJ
data  ||| S:1004 E:1009 ||| NNS
showed  ||| S:1009 E:1016 ||| VBD
that  ||| S:1016 E:1021 ||| IN
these  ||| S:1021 E:1027 ||| DT
treatment  ||| S:1027 E:1037 ||| NN
benefits  ||| S:1037 E:1046 ||| NNS
were  ||| S:1046 E:1051 ||| VBD
maintained ||| S:1051 E:1061 ||| VBN
.  ||| S:1061 E:1063 ||| .
There  ||| S:1063 E:1069 ||| EX
was  ||| S:1069 E:1073 ||| VBD
a  ||| S:1073 E:1075 ||| DT
significant  ||| S:1075 E:1087 ||| JJ
improvement  ||| S:1087 E:1099 ||| NN
in  ||| S:1099 E:1102 ||| IN
patients ||| S:1102 E:1110 ||| NNS
'  ||| S:1110 E:1112 ||| POS
functional  ||| S:1112 E:1123 ||| JJ
status  ||| S:1123 E:1130 ||| NN
as  ||| S:1130 E:1133 ||| IN
measured  ||| S:1133 E:1142 ||| VBN
by  ||| S:1142 E:1145 ||| IN
the  ||| S:1145 E:1149 ||| DT
Health  ||| S:1149 E:1156 ||| NNP
Assessment  ||| S:1156 E:1167 ||| NNP
Questionnaire  ||| S:1167 E:1181 ||| NNP
( ||| S:1181 E:1182 ||| -LRB-
HAQ ||| S:1182 E:1185 ||| NNP
)  ||| S:1185 E:1187 ||| -RRB-
change  ||| S:1187 E:1194 ||| NN
from  ||| S:1194 E:1199 ||| IN
baseline  ||| S:1199 E:1208 ||| NN
at  ||| S:1208 E:1211 ||| IN
24  ||| S:1211 E:1214 ||| CD
weeks  ||| S:1214 E:1220 ||| NNS
( ||| S:1220 E:1221 ||| -LRB-
-0.33 ||| S:1221 E:1226 ||| NNP
,  ||| S:1226 E:1228 ||| ,
p  ||| S:1228 E:1230 ||| CD
< ||| S:1230 E:1232 ||| SYM
0.001 ||| S:1232 E:1237 ||| CD
) ||| S:1237 E:1238 ||| -RRB-
.  ||| S:1238 E:1240 ||| .
The  ||| S:1240 E:1244 ||| DT
open-label  ||| S:1244 E:1255 ||| JJ
extension  ||| S:1255 E:1265 ||| NN
data  ||| S:1265 E:1270 ||| NNS
showed  ||| S:1270 E:1277 ||| VBD
that  ||| S:1277 E:1282 ||| IN
these  ||| S:1282 E:1288 ||| DT
beneficial  ||| S:1288 E:1299 ||| JJ
effects  ||| S:1299 E:1307 ||| NNS
were  ||| S:1307 E:1312 ||| VBD
also  ||| S:1312 E:1317 ||| RB
maintained  ||| S:1317 E:1328 ||| VBN
at  ||| S:1328 E:1331 ||| IN
52  ||| S:1331 E:1334 ||| CD
and  ||| S:1334 E:1338 ||| CC
104  ||| S:1338 E:1342 ||| CD
weeks ||| S:1342 E:1347 ||| NNS
.  ||| S:1347 E:1349 ||| .
However ||| S:1349 E:1356 ||| RB
,  ||| S:1356 E:1358 ||| ,
PASI  ||| S:1358 E:1363 ||| NNP
50  ||| S:1363 E:1366 ||| CD
and  ||| S:1366 E:1370 ||| CC
PASI  ||| S:1370 E:1375 ||| NNP
90  ||| S:1375 E:1378 ||| CD
at  ||| S:1378 E:1381 ||| IN
14  ||| S:1381 E:1384 ||| CD
weeks ||| S:1384 E:1389 ||| NNS
,  ||| S:1389 E:1391 ||| ,
and  ||| S:1391 E:1395 ||| CC
all  ||| S:1395 E:1399 ||| DT
of  ||| S:1399 E:1402 ||| IN
the  ||| S:1402 E:1406 ||| DT
PASI  ||| S:1406 E:1411 ||| NNP
outcomes  ||| S:1411 E:1420 ||| NNS
at  ||| S:1420 E:1423 ||| IN
24  ||| S:1423 E:1426 ||| CD
weeks ||| S:1426 E:1431 ||| NNS
,  ||| S:1431 E:1433 ||| ,
were  ||| S:1433 E:1438 ||| VBD
not  ||| S:1438 E:1442 ||| RB
performed  ||| S:1442 E:1452 ||| VBN
on  ||| S:1452 E:1455 ||| IN
the  ||| S:1455 E:1459 ||| DT
basis  ||| S:1459 E:1465 ||| NN
of  ||| S:1465 E:1468 ||| IN
intention-to-treat  ||| S:1468 E:1487 ||| JJ
analysis ||| S:1487 E:1495 ||| NN
.  ||| S:1495 E:1497 ||| .
Furthermore ||| S:1497 E:1508 ||| RB
,  ||| S:1508 E:1510 ||| ,
analyses  ||| S:1510 E:1519 ||| NNS
of  ||| S:1519 E:1522 ||| IN
the  ||| S:1522 E:1526 ||| DT
24-week  ||| S:1526 E:1534 ||| CD
data  ||| S:1534 E:1539 ||| NNS
were  ||| S:1539 E:1544 ||| VBD
less  ||| S:1544 E:1549 ||| RBR
robust ||| S:1549 E:1555 ||| JJ
,  ||| S:1555 E:1557 ||| ,
failing  ||| S:1557 E:1565 ||| VBG
to  ||| S:1565 E:1568 ||| TO
adjust  ||| S:1568 E:1575 ||| VB
for  ||| S:1575 E:1579 ||| IN
treatment  ||| S:1579 E:1589 ||| NN
contamination  ||| S:1589 E:1603 ||| NN
due  ||| S:1603 E:1607 ||| JJ
to  ||| S:1607 E:1610 ||| TO
patient  ||| S:1610 E:1618 ||| JJ
crossover  ||| S:1618 E:1628 ||| NN
at  ||| S:1628 E:1631 ||| IN
week  ||| S:1631 E:1636 ||| NN
16 ||| S:1636 E:1638 ||| CD
.  ||| S:1638 E:1640 ||| .
The  ||| S:1640 E:1644 ||| DT
manufacturer  ||| S:1644 E:1657 ||| NN
conducted  ||| S:1657 E:1667 ||| VBD
a  ||| S:1667 E:1669 ||| DT
mixed  ||| S:1669 E:1675 ||| JJ
treatment  ||| S:1675 E:1685 ||| NN
comparison  ||| S:1685 E:1696 ||| NN
( ||| S:1696 E:1697 ||| -LRB-
MTC ||| S:1697 E:1700 ||| NNP
)  ||| S:1700 E:1702 ||| -RRB-
analysis ||| S:1702 E:1710 ||| NN
.  ||| S:1710 E:1712 ||| .
The  ||| S:1712 E:1716 ||| DT
ERG  ||| S:1716 E:1720 ||| NNP
considered  ||| S:1720 E:1731 ||| VBD
the  ||| S:1731 E:1735 ||| DT
assumption  ||| S:1735 E:1746 ||| NN
of  ||| S:1746 E:1749 ||| IN
exchangeability  ||| S:1749 E:1765 ||| NN
between  ||| S:1765 E:1773 ||| IN
the  ||| S:1773 E:1777 ||| DT
trials  ||| S:1777 E:1784 ||| NNS
for  ||| S:1784 E:1788 ||| IN
the  ||| S:1788 E:1792 ||| DT
purpose  ||| S:1792 E:1800 ||| NN
of  ||| S:1800 E:1803 ||| IN
the  ||| S:1803 E:1807 ||| DT
MTC  ||| S:1807 E:1811 ||| NNP
analysis  ||| S:1811 E:1820 ||| NN
to  ||| S:1820 E:1823 ||| TO
be  ||| S:1823 E:1826 ||| VB
acceptable ||| S:1826 E:1836 ||| JJ
,  ||| S:1836 E:1838 ||| ,
and  ||| S:1838 E:1842 ||| CC
the  ||| S:1842 E:1846 ||| DT
statistical  ||| S:1846 E:1858 ||| JJ
approach  ||| S:1858 E:1867 ||| NN
in  ||| S:1867 E:1870 ||| IN
the  ||| S:1870 E:1874 ||| DT
MTC  ||| S:1874 E:1878 ||| NNP
analysis  ||| S:1878 E:1887 ||| NN
to  ||| S:1887 E:1890 ||| TO
be  ||| S:1890 E:1893 ||| VB
reliable ||| S:1893 E:1901 ||| JJ
.  ||| S:1901 E:1903 ||| .
Regarding  ||| S:1903 E:1913 ||| VBG
the  ||| S:1913 E:1917 ||| DT
safety  ||| S:1917 E:1924 ||| NN
evaluation  ||| S:1924 E:1935 ||| NN
of  ||| S:1935 E:1938 ||| IN
golimumab ||| S:1938 E:1947 ||| NN
,  ||| S:1947 E:1949 ||| ,
the  ||| S:1949 E:1953 ||| DT
manufacturer  ||| S:1953 E:1966 ||| NN
failed  ||| S:1966 E:1973 ||| VBD
to  ||| S:1973 E:1976 ||| TO
provide  ||| S:1976 E:1984 ||| VB
longer-term  ||| S:1984 E:1996 ||| JJ
data  ||| S:1996 E:2001 ||| NNS
or  ||| S:2001 E:2004 ||| CC
to  ||| S:2004 E:2007 ||| TO
consider  ||| S:2007 E:2016 ||| VB
adverse  ||| S:2016 E:2024 ||| JJ
event  ||| S:2024 E:2030 ||| NN
data  ||| S:2030 E:2035 ||| NNS
of  ||| S:2035 E:2038 ||| IN
golimumab  ||| S:2038 E:2048 ||| NN
from  ||| S:2048 E:2053 ||| IN
controlled  ||| S:2053 E:2064 ||| JJ
studies  ||| S:2064 E:2072 ||| NNS
in  ||| S:2072 E:2075 ||| IN
other  ||| S:2075 E:2081 ||| JJ
conditions ||| S:2081 E:2091 ||| NNS
,  ||| S:2091 E:2093 ||| ,
such  ||| S:2093 E:2098 ||| JJ
as  ||| S:2098 E:2101 ||| IN
rheumatoid  ||| S:2101 E:2112 ||| JJ
arthritis  ||| S:2112 E:2122 ||| NN
and  ||| S:2122 E:2126 ||| CC
ankylosing  ||| S:2126 E:2137 ||| JJ
spondylitis ||| S:2137 E:2148 ||| NN
.  ||| S:2148 E:2150 ||| .
Although  ||| S:2150 E:2159 ||| IN
the  ||| S:2159 E:2163 ||| DT
adverse  ||| S:2163 E:2171 ||| JJ
effect  ||| S:2171 E:2178 ||| NN
profile  ||| S:2178 E:2186 ||| NN
of  ||| S:2186 E:2189 ||| IN
golimumab  ||| S:2189 E:2199 ||| NN
appears  ||| S:2199 E:2207 ||| VBZ
similar  ||| S:2207 E:2215 ||| JJ
to  ||| S:2215 E:2218 ||| TO
other  ||| S:2218 E:2224 ||| JJ
anti-tumour  ||| S:2224 E:2236 ||| JJ
necrosis  ||| S:2236 E:2245 ||| JJ
factor  ||| S:2245 E:2252 ||| NN
( ||| S:2252 E:2253 ||| -LRB-
TNF ||| S:2253 E:2256 ||| NNP
)  ||| S:2256 E:2258 ||| -RRB-
agents ||| S:2258 E:2264 ||| NNS
,  ||| S:2264 E:2266 ||| ,
the  ||| S:2266 E:2270 ||| DT
longer-term  ||| S:2270 E:2282 ||| JJ
safety  ||| S:2282 E:2289 ||| NN
profile  ||| S:2289 E:2297 ||| NN
of  ||| S:2297 E:2300 ||| IN
golimumab  ||| S:2300 E:2310 ||| NN
remains  ||| S:2310 E:2318 ||| VBZ
uncertain ||| S:2318 E:2327 ||| JJ
.  ||| S:2327 E:2329 ||| .
The  ||| S:2329 E:2333 ||| DT
manufacturer ||| S:2333 E:2345 ||| NN
's  ||| S:2345 E:2348 ||| POS
submission  ||| S:2348 E:2359 ||| NN
presented  ||| S:2359 E:2369 ||| VBD
a  ||| S:2369 E:2371 ||| DT
decision  ||| S:2371 E:2380 ||| NN
model  ||| S:2380 E:2386 ||| NN
to  ||| S:2386 E:2389 ||| TO
compare  ||| S:2389 E:2397 ||| VB
etanercept ||| S:2397 E:2407 ||| NNS
,  ||| S:2407 E:2409 ||| ,
infliximab ||| S:2409 E:2419 ||| NN
,  ||| S:2419 E:2421 ||| ,
golimumab  ||| S:2421 E:2431 ||| NN
and  ||| S:2431 E:2435 ||| CC
adalimumab  ||| S:2435 E:2446 ||| FW
versus  ||| S:2446 E:2453 ||| FW
palliative  ||| S:2453 E:2464 ||| FW
care  ||| S:2464 E:2469 ||| NN
for  ||| S:2469 E:2473 ||| IN
patients  ||| S:2473 E:2482 ||| NNS
with  ||| S:2482 E:2487 ||| IN
PsA ||| S:2487 E:2490 ||| JJ
.  ||| S:2490 E:2492 ||| .
In  ||| S:2492 E:2495 ||| IN
the  ||| S:2495 E:2499 ||| DT
base-case  ||| S:2499 E:2509 ||| JJ
model ||| S:2509 E:2514 ||| NN
,  ||| S:2514 E:2516 ||| ,
73 ||| S:2516 E:2518 ||| CD
%  ||| S:2518 E:2520 ||| NN
of  ||| S:2520 E:2523 ||| IN
the  ||| S:2523 E:2527 ||| DT
cohort  ||| S:2527 E:2534 ||| NN
of  ||| S:2534 E:2537 ||| IN
patients  ||| S:2537 E:2546 ||| NNS
were  ||| S:2546 E:2551 ||| VBD
assumed  ||| S:2551 E:2559 ||| VBN
to  ||| S:2559 E:2562 ||| TO
have  ||| S:2562 E:2567 ||| VB
significant  ||| S:2567 E:2579 ||| JJ
psoriasis  ||| S:2579 E:2589 ||| NNS
( ||| S:2589 E:2590 ||| -LRB-
>  ||| S:2590 E:2592 ||| CD
3 ||| S:2592 E:2593 ||| CD
%  ||| S:2593 E:2595 ||| NN
of  ||| S:2595 E:2598 ||| IN
body  ||| S:2598 E:2603 ||| NN
surface  ||| S:2603 E:2611 ||| NN
area ||| S:2611 E:2615 ||| NN
) ||| S:2615 E:2616 ||| -RRB-
.  ||| S:2616 E:2618 ||| .
Estimates  ||| S:2618 E:2628 ||| NNS
of  ||| S:2628 E:2631 ||| IN
the  ||| S:2631 E:2635 ||| DT
effectiveness  ||| S:2635 E:2649 ||| NN
of  ||| S:2649 E:2652 ||| IN
anti-TNF  ||| S:2652 E:2661 ||| JJ
agents  ||| S:2661 E:2668 ||| NNS
in  ||| S:2668 E:2671 ||| IN
terms  ||| S:2671 E:2677 ||| NNS
of  ||| S:2677 E:2680 ||| IN
PsARC ||| S:2680 E:2685 ||| NNP
,  ||| S:2685 E:2687 ||| ,
HAQ  ||| S:2687 E:2691 ||| NNP
change  ||| S:2691 E:2698 ||| NN
and  ||| S:2698 E:2702 ||| CC
PASI  ||| S:2702 E:2707 ||| NNP
change  ||| S:2707 E:2714 ||| NN
were  ||| S:2714 E:2719 ||| VBD
obtained  ||| S:2719 E:2728 ||| VBN
from  ||| S:2728 E:2733 ||| IN
an  ||| S:2733 E:2736 ||| DT
MTC  ||| S:2736 E:2740 ||| NNP
analysis  ||| S:2740 E:2749 ||| NN
of  ||| S:2749 E:2752 ||| IN
RCT  ||| S:2752 E:2756 ||| NNP
data ||| S:2756 E:2760 ||| NNS
.  ||| S:2760 E:2762 ||| .
The  ||| S:2762 E:2766 ||| DT
manufacturer  ||| S:2766 E:2779 ||| NN
failed  ||| S:2779 E:2786 ||| VBD
to  ||| S:2786 E:2789 ||| TO
calculate  ||| S:2789 E:2799 ||| VB
incremental  ||| S:2799 E:2811 ||| JJ
cost-effectiveness  ||| S:2811 E:2830 ||| JJ
ratios  ||| S:2830 E:2837 ||| NNS
( ||| S:2837 E:2838 ||| -LRB-
ICERs ||| S:2838 E:2843 ||| NNP
)  ||| S:2843 E:2845 ||| -RRB-
correctly  ||| S:2845 E:2855 ||| RB
by  ||| S:2855 E:2858 ||| IN
comparing  ||| S:2858 E:2868 ||| VBG
golimumab  ||| S:2868 E:2878 ||| NN
with  ||| S:2878 E:2883 ||| IN
palliative  ||| S:2883 E:2894 ||| JJ
care  ||| S:2894 E:2899 ||| NN
instead  ||| S:2899 E:2907 ||| RB
of  ||| S:2907 E:2910 ||| IN
the  ||| S:2910 E:2914 ||| DT
most  ||| S:2914 E:2919 ||| RBS
cost-effective  ||| S:2919 E:2934 ||| JJ
alternative  ||| S:2934 E:2946 ||| NN
( ||| S:2946 E:2947 ||| -LRB-
etanercept ||| S:2947 E:2957 ||| LS
) ||| S:2957 E:2958 ||| -RRB-
.  ||| S:2958 E:2960 ||| .
Despite  ||| S:2960 E:2968 ||| IN
the  ||| S:2968 E:2972 ||| DT
manufacturer ||| S:2972 E:2984 ||| NN
's  ||| S:2984 E:2987 ||| POS
claim  ||| S:2987 E:2993 ||| NN
that  ||| S:2993 E:2998 ||| IN
golimumab  ||| S:2998 E:3008 ||| NN
is  ||| S:3008 E:3011 ||| VBZ
a  ||| S:3011 E:3013 ||| DT
cost-effective  ||| S:3013 E:3028 ||| JJ
treatment  ||| S:3028 E:3038 ||| NN
option ||| S:3038 E:3044 ||| NN
,  ||| S:3044 E:3046 ||| ,
the  ||| S:3046 E:3050 ||| DT
manufacturer ||| S:3050 E:3062 ||| NN
's  ||| S:3062 E:3065 ||| POS
own  ||| S:3065 E:3069 ||| JJ
model  ||| S:3069 E:3075 ||| NN
showed  ||| S:3075 E:3082 ||| VBD
that  ||| S:3082 E:3087 ||| DT
golimumab  ||| S:3087 E:3097 ||| NN
is  ||| S:3097 E:3100 ||| VBZ
not  ||| S:3100 E:3104 ||| RB
cost-effective  ||| S:3104 E:3119 ||| JJ
compared  ||| S:3119 E:3128 ||| VBN
with  ||| S:3128 E:3133 ||| IN
other  ||| S:3133 E:3139 ||| JJ
biologics  ||| S:3139 E:3149 ||| NN
when  ||| S:3149 E:3154 ||| WRB
the  ||| S:3154 E:3158 ||| DT
ICERs  ||| S:3158 E:3164 ||| NNS
are  ||| S:3164 E:3168 ||| VBP
correctly  ||| S:3168 E:3178 ||| RB
calculated ||| S:3178 E:3188 ||| VBN
.  ||| S:3188 E:3190 ||| .
None  ||| S:3190 E:3195 ||| NN
of  ||| S:3195 E:3198 ||| IN
the  ||| S:3198 E:3202 ||| DT
sensitivity  ||| S:3202 E:3214 ||| NN
analyses  ||| S:3214 E:3223 ||| NNS
carried  ||| S:3223 E:3231 ||| VBD
out  ||| S:3231 E:3235 ||| RP
by  ||| S:3235 E:3238 ||| IN
the  ||| S:3238 E:3242 ||| DT
manufacturer  ||| S:3242 E:3255 ||| NN
or  ||| S:3255 E:3258 ||| CC
the  ||| S:3258 E:3262 ||| DT
ERG  ||| S:3262 E:3266 ||| NNP
regarding  ||| S:3266 E:3276 ||| VBG
uncertainty  ||| S:3276 E:3288 ||| NN
in  ||| S:3288 E:3291 ||| IN
the  ||| S:3291 E:3295 ||| DT
estimates  ||| S:3295 E:3305 ||| NNS
of  ||| S:3305 E:3308 ||| IN
clinical  ||| S:3308 E:3317 ||| JJ
effectiveness ||| S:3317 E:3330 ||| NN
,  ||| S:3330 E:3332 ||| ,
the  ||| S:3332 E:3336 ||| DT
acquisition  ||| S:3336 E:3348 ||| NN
and  ||| S:3348 E:3352 ||| CC
administration  ||| S:3352 E:3367 ||| NN
cost  ||| S:3367 E:3372 ||| NN
of  ||| S:3372 E:3375 ||| IN
drugs ||| S:3375 E:3380 ||| NNS
,  ||| S:3380 E:3382 ||| ,
the  ||| S:3382 E:3386 ||| DT
cost  ||| S:3386 E:3391 ||| NN
of  ||| S:3391 E:3394 ||| IN
treating  ||| S:3394 E:3403 ||| VBG
psoriasis  ||| S:3403 E:3413 ||| NNS
and  ||| S:3413 E:3417 ||| CC
the  ||| S:3417 E:3421 ||| DT
utility  ||| S:3421 E:3429 ||| NN
functions  ||| S:3429 E:3439 ||| NNS
estimated  ||| S:3439 E:3449 ||| VBN
to  ||| S:3449 E:3452 ||| TO
generate  ||| S:3452 E:3461 ||| VB
health  ||| S:3461 E:3468 ||| NN
outcomes  ||| S:3468 E:3477 ||| NNS
changed  ||| S:3477 E:3485 ||| VBD
this  ||| S:3485 E:3490 ||| DT
conclusion ||| S:3490 E:3500 ||| NN
.  ||| S:3500 E:3502 ||| .
However ||| S:3502 E:3509 ||| RB
,  ||| S:3509 E:3511 ||| ,
a  ||| S:3511 E:3513 ||| DT
key  ||| S:3513 E:3517 ||| JJ
area  ||| S:3517 E:3522 ||| NN
in  ||| S:3522 E:3525 ||| IN
determining  ||| S:3525 E:3537 ||| VBG
the  ||| S:3537 E:3541 ||| DT
cost-effectiveness  ||| S:3541 E:3560 ||| JJ
of  ||| S:3560 E:3563 ||| IN
anti-TNF  ||| S:3563 E:3572 ||| JJ
agents  ||| S:3572 E:3579 ||| NNS
is  ||| S:3579 E:3582 ||| VBZ
whether  ||| S:3582 E:3590 ||| IN
they  ||| S:3590 E:3595 ||| PRP
should  ||| S:3595 E:3602 ||| MD
be  ||| S:3602 E:3605 ||| VB
treated  ||| S:3605 E:3613 ||| VBN
as  ||| S:3613 E:3616 ||| IN
a  ||| S:3616 E:3618 ||| DT
class ||| S:3618 E:3623 ||| NN
.  ||| S:3623 E:3625 ||| .
If  ||| S:3625 E:3628 ||| IN
all  ||| S:3628 E:3632 ||| DT
anti-TNF  ||| S:3632 E:3641 ||| JJ
agents  ||| S:3641 E:3648 ||| NNS
are  ||| S:3648 E:3652 ||| VBP
considered  ||| S:3652 E:3663 ||| VBN
equally  ||| S:3663 E:3671 ||| RB
effective  ||| S:3671 E:3681 ||| JJ
then  ||| S:3681 E:3686 ||| RB
etanercept ||| S:3686 E:3696 ||| JJ
,  ||| S:3696 E:3698 ||| ,
adalimumab  ||| S:3698 E:3709 ||| NN
and  ||| S:3709 E:3713 ||| CC
golimumab  ||| S:3713 E:3723 ||| NNS
have  ||| S:3723 E:3728 ||| VBP
very  ||| S:3728 E:3733 ||| RB
nearly  ||| S:3733 E:3740 ||| RB
equal  ||| S:3740 E:3746 ||| JJ
costs  ||| S:3746 E:3752 ||| NNS
and  ||| S:3752 E:3756 ||| CC
equal  ||| S:3756 E:3762 ||| JJ
quality-adjusted  ||| S:3762 E:3779 ||| JJ
life-years  ||| S:3779 E:3790 ||| NN
( ||| S:3790 E:3791 ||| -LRB-
QALYs ||| S:3791 E:3796 ||| NNP
) ||| S:3796 E:3797 ||| -RRB-
,  ||| S:3797 E:3799 ||| ,
and  ||| S:3799 E:3803 ||| CC
all  ||| S:3803 E:3807 ||| RB
have  ||| S:3807 E:3812 ||| VB
an  ||| S:3812 E:3815 ||| DT
ICER  ||| S:3815 E:3820 ||| NNP
of  ||| S:3820 E:3823 ||| IN
about  ||| S:3823 E:3829 ||| IN
£  ||| S:3829 E:3831 ||| CD
15,000  ||| S:3831 E:3838 ||| CD
per  ||| S:3838 E:3842 ||| FW
QALY  ||| S:3842 E:3847 ||| FW
versus  ||| S:3847 E:3854 ||| FW
palliative  ||| S:3854 E:3865 ||| FW
care ||| S:3865 E:3869 ||| NN
,  ||| S:3869 E:3871 ||| ,
whereas  ||| S:3871 E:3879 ||| IN
infliximab  ||| S:3879 E:3890 ||| NN
with  ||| S:3890 E:3895 ||| IN
a  ||| S:3895 E:3897 ||| DT
higher  ||| S:3897 E:3904 ||| JJR
acquisition  ||| S:3904 E:3916 ||| NN
cost  ||| S:3916 E:3921 ||| NN
is  ||| S:3921 E:3924 ||| VBZ
dominated  ||| S:3924 E:3934 ||| VBN
by  ||| S:3934 E:3937 ||| IN
the  ||| S:3937 E:3941 ||| DT
other  ||| S:3941 E:3947 ||| JJ
biologics ||| S:3947 E:3956 ||| NN
.  ||| S:3956 E:3958 ||| .
